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ipilimumab with carboplatin/paclitaxel in
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Abstract
Background: Checkpoint blockade with ipilimumab provides long-term survival to a significant proportion of
patients with metastatic melanoma. New approaches to increase survival and to predict which patients will benefit
from treatment are needed. This phase II trial combined ipilimumab with carboplatin/paclitaxel (CP) to assess its
safety, efficacy, and to search for peripheral and tumor-based predictive biomarkers.
Methods: Thirty patients with untreated unresectable/metastatic melanoma were treated with ipilimumab and CP.
Adverse events (AEs) were monitored and response to treatment was evaluated. Tumor tissue and peripheral blood
were collected at specified time points to characterize tumor immune markers by immunohistochemistry and
systemic immune activity by multiplex assays and flow cytometry.
Results: Eighty three percent of patients received all 5 cycles of CP and 93% completed ipilimumab induction.
Serious AEs occurred in 13% of patients, and no treatment-related deaths were observed. Best Overall Response
Rate (BORR) and Disease Control Rate (DCR) were 27 and 57%, respectively. Median overall survival was 16.
2 months. Response to treatment was positively correlated with a higher tumor CD3+ infiltrate (immune score) at
baseline. NRAS and BRAF mutations were less frequent in patients who experienced clinical benefit. Assessment of
peripheral blood revealed that non-responders had elevated baseline levels of CXCL8 and CCL4, and a higher
proportion of circulating late differentiated B cells. Pre-existing high levels of chemokines (CCL3, CCL4 and CXCL8)
and advanced B cell differentiation were strongly associated with worse patient overall survival. Elevated
proportions of circulating CD8+/PD-1+ T cells during treatment were associated with worse survival.
Conclusions: The combination of ipilimumab and CP was well tolerated and revealed novel characteristics
associated with patients likely to benefit from treatment. A pre-existing systemic inflammatory state characterized
by elevation of selected chemokines and advanced B cell differentiation, was strongly associated with poor patient
outcomes, revealing potential predictive circulating biomarkers.
Trial registration: Clinicaltrials.gov, NCT01676649, registered on August 29, 2012.
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Background
Metastatic melanoma has been historically one of the
most treatment-resistant human malignancies, with a me-
dian survival of 6–9 months with standard chemotherapy
[1]. Recently, major strides in the treatment of advanced
melanoma were achieved with the approval of two classes
of therapies, targeting the MAPK pathway and immune
checkpoints. Ipilimumab, a fully humanized monoclonal
antibody targeting cytotoxic T-lymphocyte-associated pro-
tein 4 (CTLA-4) and a negative regulator of T-cell activa-
tion, was the first immunotherapeutic agent shown to
prolong survival in this disease [2, 3]. Pivotal studies with
ipilimumab demonstrated increased overall survival (OS)
as a single agent (10.1 months) and in combination with
DTIC (11.2 months). Combining ipilimumab with other
treatment modalities to increase its efficacy and searching
for predictive biomarkers have been areas of intense
research [4–9]. After failure of immune checkpoint inhibi-
tors or in patients progressing rapidly after BRAF and
MEK inhibitors, chemotherapies, such as carboplatin and
paclitaxel (CP), are still used to treat rapidly growing
metastatic melanoma.
Previous studies have demonstrated a role for chemo-
therapeutic agents in promoting anti-tumor immunity
through several mechanisms. Platinum compounds have
been found to induce immunogenic cell death [10, 11], a
functionally distinct type of apoptosis that elicits tumor-
specific cognate immune responses [12]. Preclinical
studies show tumor cells treated with taxanes or plat-
inum compounds lead to increased cytotoxic T-cell acti-
vation [13–15]. Paclitaxel has also been implicated in
direct inhibition of myeloid-derived suppressor cells
(MDSCs), a heterogeneous population of cells that are
defined by their myeloid origin, immature state and abil-
ity to potently suppress T cell responses [16]. Addition
of chemotherapy has been shown to enhance anti-
CTLA-4 antitumor activity in animal models [17]. Thus,
there is a good rationale to combine immune checkpoint
inhibitors, such as ipilimumab, with platinum com-
pounds like carboplatin and taxanes such as paclitaxel.
Safety and anti-tumor efficacy of this combination was
evaluated. This study also sought to prospectively iden-
tify cellular and/or molecular predictive biomarkers.
Methods
Study design and treatment
Eligible patients were men and women ≥ 18 years with a
histologic diagnosis of untreated, unresectable Stage III/
Stage IV melanoma. Prior treatment with BRAF inhibi-
tors in the metastatic setting was permitted. Patients had
measurable or evaluable disease, Eastern Cooperative
Oncology Group (ECOG) performance status ≤ 1 and
adequate bone marrow, liver, and renal function at study
entry. Patients with symptomatic brain metastases,
autoimmune disease, peripheral neuropathy ≥ Grade 2,
prior treatment with a CD137 agonist or a CTLA-4
agonist/inhibitor, chronic use of immunosuppressive
drugs or of systemic corticosteroids were excluded.
Treatment consisted of carboplatin (AUC 6)/paclitaxel
(175 mg/m2) × 5 cycles and ipilimumab (3 mg/kg × 4 cy-
cles) every 3 weeks. Each CP treatment was preceded by
dexamethasone premedication. Two different dosing
schedules were used, patients were randomly assigned in a
1:2 scheme to receive ipilimumab either concurrently
(Arm A, 10 patients) with CP or sequentially 1 week apart
(Arm B, 20 patients), starting at Cycle 2. Patients were
stratified according to previous treatment with a BRAF in-
hibitor. Physicians had the option of retreating patients
with either ipilimumab alone or in combination with CP if
they experienced disease progression following objective
response (PR, CR) or SD lasting for 3 months or more.
Supportive measures and/or secondary prophylaxis were
allowed for CP induced hematologic toxicity.
The primary objective was to determine the safety and
tolerability of two schedules of ipilimumab in combin-
ation with CP. Secondary objectives were to determine
putative early cellular and/or molecular biomarkers for
therapy response; to measure anti-tumor efficacy (OS,
overall response rate (ORR), PFS, and clinical benefit
rate (CBR; ORR + stable disease (SD) ≥ 24 weeks)) by
irRC and mWHO response criteria [18].
Response evaluations (progressive disease (PD), stable
disease (SD), partial response (PR), complete response
(CR)) were defined according to mWHO and irRC guide-
lines [18]. mWHO results are available in Additional file 1:
Figure S1 and Additional file 2: Table S3. Tumor assess-
ments were performed at screening, weeks 8, 16, 24 and
approximately every 12 weeks thereafter. Safety assess-
ments included vital signs, physical examinations, labora-
tory tests, and adverse event reporting (AEs). AEs were
graded using the Common Toxicity Criteria for Adverse
Events, version 4.0. AEs were recorded from the first study
medication dose. SAEs were recorded following consent
signature until 70 days from discontinuation of investiga-
tional products.
The study was conducted in accordance with the
Declaration of Helsinki of 1975. The protocol was ap-
proved by local ethics committees. All participants gave
written informed consent for the study.
Correlative studies
DNA was extracted from formalin-fixed and paraffin-
embedded tissue sections containing at least 30% tumor
cells (cobas®, Roche) collected at screening. Mutation
analysis of BRAF V600 (cobas® kits, Roche) was per-
formed on a cobas® z480 instrument and confirmed by
sequencing (Sanger). For NRAS, mutation analysis was
performed using the NRAS Mutation detection kit
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(EntroGen) on an LC480 platform (Roche). All manipula-
tions were performed according to College of American
Pathologists-compliant standard operating procedures of
the Jewish General Hospital Molecular Pathology Centre.
Immunohistochemistry with Ventana Benchmark anti-
bodies towards CD3 (clone 2GV6), CD4 (clone SP35),
CD8 (clone 1A5) and PD-L1 (clone SP142) was per-
formed according to standard automated protocols and
quantified in agreement with REMARK guidelines [19].
PD-L1 expression was assessed semi-quantitatively as
previously described [20]. The immune score was ob-
tained from semi-quantitative prevalence of CD3+ cells
noted as absent (0), focal (1), moderate (2) or severe (3)
as previously described [21].
Blood samples were collected from patients at base-
line, weeks 1, 2, 4, 7, 10, 13, 16, 24 and at the end of
study. Blood was also obtained from six normal donors
(ND). Peripheral blood collection and processing were
done as previously described [22]. PBMCs suspended in
human serum albumin solution were stored at −80 °C.
Cell surface staining was performed as described previ-
ously [22, 23] using antibodies (BD Biosciences) listed in
Additional file 2: Table S6. Dead cells were excluded
with the Live/Dead Fixable Dead Cell kit (Invitrogen).
Flow cytometry data were acquired using a BDFortessa
instrument (BD Biosciences) and analyzed using FlowJo
software (Tree Star). Peripheral soluble cytokines/che-
mokines/soluble receptors (Additional file 2: Table S7)
were measured from cryopreserved plasma. All kit
components from V-plex Ultra-Sensitive kit (Meso Scale
Discovery) were processed as per the manufacturer’s in-
structions. Electroluminescent data were analyzed with a
four-parameter logistic curve fit using MSD Discovery
Workbench.
IgG, IgA and IgM concentrations were determined in a
standard ELISA as previously previously described [14].
Baseline values from patients and from the normal donors
were inside the accepted ranges of reference values for
clinical diagnostic purposes (total IgG, 7.0–16.0 g/l; total
IgA, 0.7–4.0 g/l; total IgM, 0.4–2.3 g/l).
Statistical analyses
This study was designed as a pilot study on a limited
number of patients to gain insight on safety and efficacy
of the combination of ipilimumab and CP and identify
putative biomarkers associated with response. Patients
and disease characteristics were analyzed using descrip-
tive statistics and expressed as either relative frequency
(percentages) for discrete variables or median for
continuous variables. Comparisons between patient
response groups at baseline and throughout treatment
were evaluated by ANOVA. Correlations between muta-
tion and tumor immune profiles and best overall
response (BOR) were determined using Chi-square and
Pearson correlation tests. Effect of groups and time
points and their interaction in blood samples were
assessed with linear mixed effect models, multiple com-
parisons specified in figure legends were done where
interactions were not significant. Univariate cox propor-
tional hazards regression analyses were used to assess
correlation of variables with OS. Chemokine, Bm2 and
eBm5 + Bm5 levels were logarithmically transformed
prior to regression analyses. OS Kaplan–Meier curves
were compared by the log-rank test. Cutoff thresholds
defining high or low levels were established from the
mean value of a given variable from all patients. A P
value < 0.05 was considered statistically significant.
Statistical analyses were performed with SPSS 25
software (SPSS Inc.), GraphPad Prism 6.01, and R
software i386 3.0.2 [24].
Results
Patient selection
Thirty patients were enrolled onto the study from
December 2012 until October 2013 (Table 1, Additional
file 2: Table S1). Fifty-seven percent of patients had M1c
disease, and 33% of patients had LDH levels higher than
the upper limit of normal at baseline. Seventeen percent
of patients had received prior adjuvant therapy. Nine pa-
tients had a BRAF mutated melanoma, of whom six had
been treated with a BRAF inhibitor in the metastatic set-
ting. Eighty-three percent of patients received all five cy-
cles of CP, and 93% received all four doses of
ipilimumab. One patient did not receive ipilimumab be-
cause of early clinical progression. Six patients meeting
the retreatment criteria were retreated with either ipili-
mumab/CP (2/6) or ipilimumab alone (4/6).
Toxicity
The most common Grade 3–4 adverse events found in
≥ 10% of patients were diarrhea, neutropenia and
thrombocytopenia (Table 2, Additional file 2: Table S2).
The rate of febrile neutropenia was 7% (2/30). Four pa-
tients (13%) had treatment-related SAEs. Two patients
discontinued chemotherapy because of drug-related AEs
(Grade 3 ALT and Grade 4 neutropenia). Four patients
had infusion related reactions to paclitaxel. Grade 3–4
AEs related to ipilimumab were found in 13% of
patients. Twenty percent (6/30) of patients received
steroids for immune-related adverse events (irAEs): one
patient with Grade 3 autoimmune colitis, two patients
with Grade 3 diarrhea, two patients with Grade 2 endo-
crinopathy, and one patient with Grade 2 rash. One
patient discontinued ipilimumab because of an irAE
(Grade 3 autoimmune colitis) during the re-treatment
period. No drug-related deaths were reported. Adverse
events were comparable between treatment arms
(Additional file 2: Table S2).
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Efficacy
Patients were followed for up to 46.9 months, with an
overall median follow-up of 37.6 months. The median
OS was 16.2 months for the entire cohort (Figure 1a).
The rate of OS for all patients was 56.7%, 43.3% and
36.7% at 1, 2 and 3 years, respectively. The median PFS
was 5.8 months by irRC for all patients (Figure 1b). The
best overall response rate (BORR; CR + PR), rate of dis-
ease control (DCR; CR + PR + SD), and clinical benefit
rate (CBR; CR, PR or SD ≥ 24 weeks) for 30 evaluable
patients were 27%, 57% and 43% by irRC, respectively
(Table 3). The two mucosal patients had a BOR of PR
whereas the three ocular patients all had PD.
Table 1 Demographic and baseline characteristics of the patients
Patient Characteristics ALL patients
(Number (percent))
Total no. of patients 30 (100)










≤ ULNa 20 (67)








Unknown primary 1 (3)
BRAF status
BRAF mutated (V600E) 9 (30)
BRAF wild type 21 (70)
Prior therapies**
Prior adjuvant therapy 5 (17)
Prior therapy with a BRAF inhibitor 6 (20)
Brain metastases
Patients without brain metastases 26 (87)
Patients with brain metastases 4 (13)
aULN denotes upper limit of the normal, ** One patient (3%) received 2 weeks
a of Temozolomide
Table 2 Adverse events
ALL Patients (n = 30)
Total Grade3/4/5
All adverse events
Any event 30 (100) 21 (70)
Hepatotoxicity
high ALT 4 (13) 2 (7)
Gastrointestinal Disorders
nausea 21 (70) 1 (3)
vomiting 14 (47) 0
diarrhea 23 (77) 3 (10)
C. difficile colitis 1 (3) 1 (3)
Electrolyte
hypophosphatemia 4 (13) 2 (7)
hypokalemia 6 (20) 1 (3)
hypomagnesemia 8 (27) 1 (3)
Hematological
anemia 4 (13) 2 (7)
febrile neutropenia 2 (7) 2 (7)
neutropenia 8 (27) 5 (17)
thrombocytopenia 6 (20) 3 (10)
Nervous System
seizure 2 (7) 1 (3)
vasovagal reaction 1 (3) 1 (3)
Infection
pneumonia 1 (3) 1 (3)
Constitutional
fatigue 17 (57) 2 (7)
Vascular Disorder
pulmonary embolism 1 (3) 1 (3)
Immune-related adverse events
Any event 26 (87) 4 (13)
Gastrointestinal Disorders
diarrhea 11 (37) 2 (7)
vomiting 6 (20) 0
autoimmune colitis 1 (3) 1 (3)
Endocrine
hypothyroidism 1 (3) 0
pituitary disorder 1 (3) 0
Skin Disorders
rash 7 (23) 0
pruritus 9 (30) 0
urticaria 1 (3) 0
vitiligo 1 (3) 0
erythroderma 1 (3) 0
Constitutional
fatigue 11 (37) 1 (3)
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Tumor correlative studies
Prevalence of BRAF and NRAS mutations, immune
infiltration and PD-L1 expression in the tumor sam-
ples obtained pre-treatment were classified according
to response. BRAF, NRAS and concurrent BRAF/
NRAS mutations in pre-treatment samples were found
in 8/30 (27%, all V600E), 2/30 (7%, both Q61R) and
1/30 (3%, V600E/Q61R) cases, respectively. Mutations
in these genes were more frequently observed in PD
patients (9/17) compared to the patients that achieved
clinical benefit (2/13, p = 0.034, Chi-square 4.474,
Figure 2a). No correlation between BRAF and/or
NRAS mutation status and OS was observed. Baseline
immune score reflecting prevalence of CD3+ cells in
tumor samples directly correlated with BORR
(Pearson correlation 0.487, p = 0.01, Figure 2b).
Immunohistochemistry analysis of PD-L1 expression
at baseline was performed on 22 cases. Twenty-seven
percent of cases (6/22) harbored greater than 5% of
PD-L1 positive melanoma cells. Lack of PD-L1 ex-
pression (<5%) was most frequently observed in irPD
(10/12 samples (83%) were PD-L1 negative) compared
to SD (1/4 samples (25%) and PR + CR (3/6 samples
(50%) were PD-L1 negative) but this did not reach
statistical significance (Additional file 2: Table S4). No
correlation between the percentage of PD-L1 positive
melanoma cells, immune score or BOR or OS was
found (Figure 2c, Additional file 2: Table S4,
Additional file 2: Table S5).
Peripheral blood correlative studies: pre-treatment
inflammatory status is associated with poor patient
outcomes
Pre-treatment soluble and cellular inflammatory markers
were studied and correlated with patient outcomes. Base-
line levels of 22 peripheral soluble cytokines/chemokines/
soluble receptors were measured by multiplex assay (see
Additional file 2: Table S7 for the panel used) in the per-
ipheral blood of patients and normal donors (ND). irPD
patients had elevated baseline plasma levels of CCL4 and
CXCL8 chemokines (1042 and 103 pg/mL, respectively)
compared to patients with irSD and irPR who had levels
similar to ND (131 and 12 pg/mL, Fig. 3a, p < 0.05). No
statistically significant differences were detected for other
soluble circulating molecules, including CCL3.
Elevated circulating CCL3 (> 67 pg/ml), CCL4 (>
600 pg/ml) and CXCL8 (> 76 pg/ml) correlated with poor
OS (Hazard Ratio (HR) =2.8 (95%CI:1.17–6.65), p < 0.016;
HR = 8.4 (95%CI:2.86–24.44), p < 0.0001 and HR = 3.5
(95%CI:1.43–8.7), p < 0.004 respectively, Fig. 3b). In
patients with an elevation of any of CCL3 or CCL4 or
CXCL8, OS was significantly worse (HR = 2.89
(95%CI:1.19–7.05), p = 0.015, Figure 3b, bottom right).
Pre-treatment levels of CCL3 and CCL4 as continuous
variables revealed a statistically predictive significance for
OS, HR: 14.14 (95%CI:1.211–165.25), p = 0.035 and 5.941
(95%CI:2.06–17.12), p = 0.001, respectively (Additional file
2: Table S5). High levels of CCL4 were also associated




1-year OS (%) 56.7
2-year OS (%) 43.3






































Fig. 1 General Kaplan-Meier survival curves – Overall patient survival
(a) as of February 17th 2017, PFS by immune-related (irRC) (b) criteria.
Censored data are shown as open boxes on graphs
Table 3 Tumor response (immune related - irRC)
Response All patients
n = 30









ir immune related, BOR best overall response, CR complete response, PR partial
response, SD stable disease, PD progressive disease, BORR best overall
response rate, DCR disease control rate (CR + PR + SD), CBR clinical benefit
rate (CR + PR + SD ≥ 24 weeks)
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(p = 0.0179, two-tailed unpaired t test). The data sug-
gest that elevation of the above-mentioned chemo-
kines reveal a pre-existing state of inflammation for
patients that predict a poor outcome to therapy with
ipilimumab and CP.
Immunophenotyping of PBMCs pre-study treatment re-
vealed no significant changes in the frequency of major
immune cell populations (Additional file 1: Figure S2).
Analysis of T cell subpopulations suggested that objective
responders (irPR + irCR) had a lower proportion of circu-
lating activated CD25+CD4+ effector T cells (1% of CD25+
cells within the effector CD4+ T cell gate) compared to pa-
tients with irPD, irSD and ND (mean of 3.3% (p = ns),
4.5% (p = 0.042) and 5.7% (p = 0.006), respectively as
shown in Additional file 1: Figure S3C. However, increase
in this population had no impact on OS (Additional file 1:
Figure S3D, Additional file 2: Table S5). Lower levels of
additional activation markers on CD4+ and CD8+ T cell
subsets where seen in responding patients (CR + PR)
although not statistically significant (Additional file 1:
Figure S3A-B).
B lymphocyte differentiation pattern was assessed
from peripheral blood to evaluate pre-existing inflamma-
tory status; more advanced B cell differentiation indi-
cates an ongoing immune response. Indeed, patient
response to treatment was associated with their baseline
activation pattern of circulating B cells. Circulating B
cell subsets from irPD patients displayed a shift towards
a late activation/memory phenotype based on surface
IgD (sIgD) and CD38 expression [25] (Figure 4a). Specif-
ically, the Bm2 subset (IgD+CD38int, mature resting B
cell) represented 44% of total CD19+ cells in irPD pa-
tients, compared to 64% in irPR + irCR (p < 0.05) and
67% in irSD (p < 0.05) patients (ND at 73.9%, p < 0.01
when compared to irPD; Figure 4a). The eBm5 + Bm5
subsets (memory B cells, IgD−CD38int/lo) represented
42.1% in irPD compared to 19% in irPR + irCR (p < 0.05)
and 19.8% in irSD (p < 0.05) patients. ND was similar to
responders at 18.2% (Figure 4a). Moreover, pre-existing
advanced B cell differentiation had a major impact on
OS, where low levels of early differentiated Bm2 (<57%)
was strongly associated with poor survival: HR = 0.26
(95%CI:0.09–0.69), p = 0.004 (Figure 4b). Conversely,
high eBm5 + Bm5 (>14%) levels were strongly associated
with better OS: HR = 2.65 (95%CI:1.07–6.53), p = 0.029,
Figure 4b). An association with OS was also observed
when evaluating baseline Bm2 and eBm5 + Bm5 as
continuous variables (HR = 0.113 (95%CI 0.023–0.549),
p = 0.007 and HR = 10.27 (95%CI:1.30–80.96), p = 0.027,
respectively, Additional file 2: Table S5). These results
show that pre-activated B cell differentiation status was
associated with poor outcome.
OS was evaluated in patients with favorable B cell dif-
ferentiation (i.e. high Bm2) combined with low levels of
at least one described chemokine. These groups demon-
strated highly significant improvements in OS (Bm2hi/
CCL3lo HR = 0.14 (95%CI:0.04–0.49) p = 0.0004; Bm2hi/
CCL4lo HR = 0.21 (95%CI:0.08–0.57), p = 0.001; and
Bm2hi/CXCL8lo HR = 0.29 (95%CI:0.11–0.76), p = 0.007,
Figure 5). Finally, patients with high levels of Bm2 and
low levels of all 3 chemokines similarly displayed im-
proved OS (HR = 0.19 (95%CI:0.05–0.65), p = 0.003).
a b c
Fig. 2 Intra-tumoral biomarkers linked to clinical outcome. a Number of patients with a BRAF (black), NRAS (orange) or BRAF/NRAS double (orange
hatched) mutation in the PD and combined CBR group (CBR; CR, PR or SD ≥ 24 weeks). The frequency of BRAF and NRAS mutations in PD is
significantly higher compared to CBR (Χ2 = 4.474, p = 0.03) b Graphical presentation of the baseline immune score (0: absent; 1: low; 2: moderate; 3:
high peri- and intratumor CD3-+ cells) per response group (irRC criteria). Mutations type for each sample is indicated: BRAF (black), NRAS (orange) or
BRAF/NRAS double (orange hatched). A significant correlation between response group and baseline immune score was observed (Pearson correlation
0.487, p = 0.01). c Baseline immune score (1: low; 2: moderate; 3: high peri- and intra-tumor CD3+ cells) and the percentage of PD-L1 expressing melan-
oma cells. Mutations type for each sample is indicated: BRAF (black), NRAS (orange) or BRAF/NRAS double (orange hatched). A trend towards higher PD-
L1 expression with increasing baseline immune score was observed (Pearson correlation 0.386, p = 0.069). No significant difference between the per-
centage of PD-L1 positive melanoma cells in tumors with baseline immune score 1 and 3 (Mann Whitney U test p = 0.694)
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Overall, data obtained from peripheral markers col-
lected before any treatment show that increase of CCL3,
CCL4, CXCL8 or advanced B lymphocyte differentiation
status were strongly associated with worse clinical
outcomes.
Treatment was associated with changes in B cell
differentiation status and an increase in antibody production
B lymphocyte differentiation status and circulating anti-
body levels were measured throughout the treatment. In
both Bm2 and eBm5 + Bm5 subsets, the baseline differ-
ence observed in irPR + irCR compared to irPD patients
was upheld throughout the study (from a linear mixed
effect models analysis, p < 0.05 for Bm2, p < 0.01 for
eBm5 and p = 0.058 for Bm5 respectively; Figure 6a).
Conversely, study treatment was accompanied by a
change in B cell subset composition across all patient re-
sponse groups. The Bm3–4 subsets (sIgD−CD38hi), cor-
responding to centroblasts/centrocytes germinal center
B cells, increased in all patients following initial expos-
ure to ipilimumab (p < 0.05 for variation in time for all
groups, Figure 6a). The Bm3–4 subset represented over
10% of B cells at week 10, compared to 3% before treat-
ment (Fig. 6a). To investigate whether treatment had
a
b
Fig. 3 Pre-treatment peripheral chemokine levels associated with response and OS. a Baseline (pre-treatment) levels of indicated chemokines
according to response status. Each point represents a donor, average is outlined, and error bars represent SEM. ns: not significant; *: p < 0.05 from
a one-way ANOVA with Bonferroni post hoc test. b Kaplan-Meier OS curves for the indicated chemokines stratified by levels above (high) or
below (low) the mean level for each chemokine. P values were calculated using the log-rank test and are shown on each graph
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further influence on B cell activity, levels of circulating
immunoglobulins were evaluated. Circulating IgG in-
creased for all patient groups (p < 0.001), IgA also in-
creased but was not statistically significant, while IgM
levels remained unchanged (Figure 6b).
These results illustrate that B cell phenotype and func-
tion were affected in all patients receiving ipilimumab
and CP. irPD patients maintained advanced B cell differ-
entiation status throughout treatment.
Ipilimumab exposure is followed by an increase in PD-1+
T cell subsets in non-responders
The levels of selected surface markers related to T
cell function were evaluated on circulating CD4+ and
CD8+ T cells before and throughout treatment with
ipilimumab and CP. In CD4+ T cells, a trend increase
in the PD-1+ cells was observed following exposure to
ipilimumab, although this apparent increase did not
yield statistically significant correlations with response
a b
Fig. 4 Pre-treatment circulating B lymphocyte differentiation status associated with patient outcomes. a Baseline (pre-treatment) percentages of
indicated B lymphocytes differentiation status (Bm2 and eBm5 + Bm5), according to the Bm classification (sIgD and CD38; see Additional file 1:
Figure S4A for nomenclature and gating strategy), according to response status. Each point represents a donor, average is outlined, and error
bars represent SEM. ns: not significant; *: p < 0.05; **: p < 0.01, from a one-way ANOVA with Bonferroni post hoc test. b Kaplan-Meier OS curves
for the Bm2 and eBm5 + Bm5 populations, stratified by percentages above (high) or below (low) the mean percentage for each population.
P values were calculated using the log-rank test and are shown on each graph
Fig. 5 B cell subsets paired with chemokine levels correlate with OS. Kaplan-Meier OS curves comparing patients with high Bm2 population and
low levels of listed chemokine (<67 pg/ml for CCL3, or <600 pg/ml for CCL4 or <76 pg/ml for CXCL8) versus all other patients (others).
P values were calculated using the log-rank test and are shown on each graph
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or survival (Additional file 1: Figure S5A). No dis-
cernable increase was observed in CD4+ Treg cells
during treatment (Additional file 1: Figure S5B). Pre-
treatment proportions of CD4+ Treg cells did not
correlate with response or survival (Additional file 1:
Figure S5B, Additional file 2: Table S5). In contrast,
increased proportions of PD-1+CD8+ T cells were
seen following ipilimumab exposure in patients with
irPD (p < 0.05, Fig. 7). Although baseline proportions
of PD-1+CD8+ cells were not associated with response
(p = ns), responding patients had a significantly lower
proportion of PD-1+CD8+ cells than patients with
irPD at the end of the observation period (p < 0.05,
Figure 7a). There was a trend in association between
high levels of PD-1+CD8+ cells prior to start of
treatment and worse OS (HR = 2.42 (95%CI:0.95–
6.20), p = 0.057, Figure 7b). However, patients with
higher proportions of these cells in circulation during
treatment consistently had poorer OS (HR = 3.84
(95%CI:1.43–10.31), p = 0.004 at week 10; HR = 3.53
(95%CI:1.37–9.09), p = 0.005 at week 13 and HR = 2.84
(95%:1.00–8.05), p = 0.040 at week 24 (Figure 7c). A
similar association between circulating PD-1+CD8+ T
cells during treatment as a continuous variable and
OS was observed (Additional file 2: Table S5).
ICOS expression was increased uniformly across all
patient response groups on both CD4+ and CD8+ T cells
following ipilimumab exposure, as previously observed
for ipilimumab monotherapy (Additional file 1: Figure
S6; top panels [7, 26, 27]). Increase in ICOS was not as-
sociated with response or OS (Additional file 1: Figure
S6; lower panels, Additional file 2: Table S5).
Discussion
This phase II study explored the toxicity, activity and pre-
dictive biomarkers of the combination of CP with ipilimu-
mab. The study of this combination reveals manageable
toxicity, with most patients completing the full course of
treatment. IrAEs were consistent with previously pub-
lished studies [2, 28]. Our study showed fewer grade 3/4
irAEs and no immune-related hepatotoxicity, when com-
pared to ipilimumab-DTIC arm, where more than 33% of
patients experienced grade 3 or more irAEs [3]. The dif-
ference in toxicity profile may be explained by the lower
dose of ipilimumab used in this study or the use of
prophylactic corticosteroids prior to paclitaxel infusions,
thus potentially diminishing the severity of irAEs. A previ-
ous study showed higher hepatotoxicity when ipilimumab
was combined with DTIC, rather than carboplatin/pacli-
taxel [28]. The performed comprehensive immune
a bEarly differentiated IgD+ B cells Late differentiated IgD- B cells
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Fig. 6 On treatment monitoring of circulating B lymphocyte differentiation status and Ig levels. a Circulating B lymphocyte differentiation status for
each Bm population before and during treatment. Effect of response groups and time points, and their interaction were assessed with a one-way
ANOVA group comparison using a linear mixed effects models for repeated measures; between indicated groups, *: p < 0.05; **: p < 0.01. b Evaluations
of total circulating levels of IgG (top), IgA (middle) and IgM (bottom). A one-way ANOVA group comparison using a linear mixed effects models for
repeated measures statistical analysis reveals that all groups had statistical variations in time for IgG; ***: p < 0.001
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correlative study revealed new predictive circulating signa-
tures linked to pre-existing inflammatory state associated
with worse patient outcome.
The median OS (16.2 months) as well as 1-year OS
(56.7%), 2-year OS (43.3%) and 3-year OS (36.7%) were
comparable to previously published responses to ipili-
mumab in the first-line setting yet this regimen offers no
survival benefit [3, 29–32]. Similarly to Weber et al. the
observed ORR was 27% by irRC criteria [28]. The limita-
tions of cross-study comparisons are recognized. Out-
comes from the current study may have been influenced
by the small patient population with mostly normal pre-
treatment LDH, few patients with brain metastases and
most patients with ECOG of 0. The criteria used to as-
sess response (irRC versus RECIST 1.1) and the avail-
ability of additional systemic treatment options post-
progression may have affected the results.
The impact of prophylactic corticosteroids use on
anti-tumor immune responses with ipilimumab is poorly
understood and a source of concern. Sequential treat-
ment with ipilimumab and CP previously showed im-
proved progression-free survival (PFS) in non-small cell
lung carcinoma compared to concurrent treatment in a
randomized phase II trial [33]. Patients on this current
study were randomized in a 1:2 fashion favoring the se-
quential arm. Our results in melanoma suggest effective
anti-tumor activity regardless of the scheduling of cor-
ticosteroid premedication (Additional file 2: Table S3).
Understanding mechanisms that influence patient re-
sponse to immunotherapies will help shape future tar-
geting strategies of the immune response. Aspects of the
immune response were studied both systemically and
within the tumor environment. The genetic composition
of the tumor may ultimately impact on its immunogen-
icity. Although there is evidence that mutant BRAF
could trigger immune responses in melanoma cells
under certain contexts [34], our data are more consist-
ent with a diminished chance of clinical benefit to ipili-
mumab in patients with BRAF mutations [35–37].
Recent subgroup analysis results from the CheckMate
067 demonstrated a favorable OS outcome for patients
with BRAF-mutant tumors in the ipilimumab cohort in
previously untreated patients [30]. 6/9 BRAF mutated
patients had failed a BRAF inhibitor which may have
contributed to poorer outcomes. One report demon-
strated that patients with NRAS mutant metastatic mel-
anoma achieved increased clinical benefit from
ipilimumab compared to patients with BRAF/NRAS wild
type melanomas [38]. We did not confirm these results
in our study, since our three patients with NRAS mutant
melanoma all had PD as BOR.
A higher immune score in pre-treatment tumor biop-
sies correlated with BOR. This correlation is in line with
the predictive value of T cell infiltrates in regional nodal
metastases and benefit in patients treated with neoadju-
vant interferon-α-2b therapy [39, 40]. The presence of a
b
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Fig. 7 Monitoring of circulating CD8+PD-1+ levels and impact on OS. a Circulating CD8+PD-1+ T cell levels before and during treatment. Effect of
response groups and time points and their interaction were assessed with a one-way ANOVA group comparison using a linear mixed effects models
for repeated measures; *: p < 0.05 between irPD and irPR + CR groups. b-c Kaplan-Meier OS curves for the CD8+PD-1+ T cell population, stratified by
mean percentages at baseline (b, Pre) and each indicated time point (c). P values were calculated using the log-rank test and are shown on each graph
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strong immune cell infiltrate in the tumor microenviron-
ment suggests that the tumor elicits T cell infiltration
and that anti-tumor T cell activation can be enhanced by
stimulating signals such as ipilimumab.
In contrast, we found that increased systemic in-
flammation at baseline is associated with poor re-
sponse to therapy and poor OS. Non-responders
displayed baseline differences in circulating chemo-
kines CXCL8 and CCL4 in comparison to the levels of
NDs and responders. CXCL8 is associated with
chronic inflammatory states [41]. Moreover, circulat-
ing levels of CXCL8 have previously been associated
with poorer prognosis in melanoma and other malig-
nancies [42, 43], and an early increase in serum
CXCL8 after initiation of anti-PD-1 treatment was as-
sociated with poor response and survival [44]. CCL4
and CCL3 may mediate the recruitment of CD8+ T
cells and regulatory T cells within melanoma lesions
[45]. In this trial, baseline elevated circulating CCL3,
CCL4 and CXCL8, alone or in combination, were as-
sociated with substantially worse patient outcomes
(Figs. 3 and 5), thus making them potential predictive
biomarkers for patients most likely to fail treatment.
The role of chemokines in mediating resistance to
therapy remains to be investigated.
A specific skewing in B cell differentiation prior to
treatment was noted in non-responders, with higher
eBm5/Bm5 terminally differentiated B cells compared
to responders and NDs (Figure 4). This also strongly
correlated with OS. These results may reflect a general
state of inflammation in non-responders as reported in
other chronic conditions [46, 47]. B cell differentiation
status was maintained throughout the study, suggesting
that ipilimumab did not reverse this effect. Interest-
ingly, Bm3–4 population, corresponding to centro-
blasts/centrocytes antibody producing B cells, increased
with treatment in all patients, independently of clinical
outcome. Study treatment had an effect on B cell
biology, leading to fluctuations in circulating anti-
bodies. CTLA-4 has been shown to modulate B cell re-
sponses through modulation of T follicular helper, T
follicular regulatory, and T regulatory cells in animal
models [48, 49]. This is the first evidence showing that
ipilimumab treatment in humans affects B lymphocyte
differentiation and function. However, the contribution
of chemotherapy and the influence of systemic cortico-
steroids as prophylaxis remains to be established. The
impact of the treatment regimen on OS of patients
depended on the baseline B cell differentiation status,
alone or in combination with chemokines. The impres-
sive combined effect of baseline early B cell populations
and chemokines on OS needs to be validated. Indeed, if
these associations are confirmed, they might bring new
predictive circulating biomarkers to immunotherapy.
Finally, an increase in the CD8+PD-1+ T cell population
in non-responders and a robust impact on OS during
treatment could be a sign of immune exhaustion and
points to a possible escape mechanism to anti-CTLA-4. It
is likely that simultaneous targeting of multiple immune
checkpoints such as PD-1 and CTLA-4 [50] may be re-
quired to overcome compensatory mechanisms. This fur-
ther suggests that additional negative immune regulators
should be monitored after immunotherapies to identify
relevant new targets to overcome resistance mechanisms.
Conclusions
In summary, we report that ipilimumab and CP can be used
in combination yielding manageable toxicities and favorable
response, even if given concurrently. Our study revealed
tumor-related and peripheral signatures associated with ipi-
limumab/CP resistance and OS. CD3+ T cell infiltration of
the tumor correlated with good response, whereas the pres-
ence of a BRAF or NRAS mutation correlated with poor re-
sponse, especially in patients pretreated with a BRAF
inhibitor. Resistance to treatment was associated with pre-
existing systemic inflammatory state, specifically elevated
CCL4 and CXCL8, baseline B lymphocyte subset skewing,
and increased CD8+PD-1+ T lymphocytes. From a compre-
hensive basic immune monitoring, we provide evidence for
new predictive circulating biomarkers linked to OS. Larger
studies are required to validate these circulating biomarkers.
Future studies will address the safety of other checkpoint
inhibitors combined with chemotherapy and determine
whether biomarkers associated with improved outcomes to
CTLA-4 directed therapy may be relevant to the clinical ac-
tivity of inhibitors of other checkpoints.
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